Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 4/20 | 0.73 |
| ▸ | SCN2A | Q99250 | 8/20 | 0.68 |
| ▸ | HPGDS | O60760 | 8/20 | 0.58 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18122012 | 0.93 | NPY5R (0.68) | NPY5RSCN2AHPGDSSMPD3 | |
| SCHEMBL28542981 | 0.84 | SCN2A (0.64) | NPY5RSCN2AHPGDSSMPD3 | |
| SCHEMBL27843962 | 0.83 | SCN2A (0.79) | NPY5RSCN2AHPGDSSMPD3 | |
| SCHEMBL31660150 | 0.82 | NPY5R (0.65) | NPY5RSCN2AHPGDS | |
| SCHEMBL26094809 | 0.82 | NPY5R (0.65) | NPY5RSCN2AHPGDS | |
| SCHEMBL2174976 | 0.82 | SCN2A (1.00) | NPY5RSCN2AHPGDSSMPD3 | |
| SCHEMBL18122017 | 0.81 | NPY5R (0.89) | NPY5RHPGDS | |
| SCHEMBL17283469 | 0.80 | SCN2A (0.96) | NPY5RSCN2AHPGDS | |
| SCHEMBL18119999 | 0.80 | SCN2A (0.74) | NPY5RSCN2AHPGDS | |
| SCHEMBL19198972 | 0.80 | SCN2A (0.62) | NPY5RSCN2AHPGDSSMPD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160289212-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2016-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289212-A1 | HEPATITIS B ANTIVIRAL AGENTS | ZC3HAV1, HAVCR2, SLC10A1 | NPY5R 296/4885SCN2A 3990/4885HPGDS 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.